Your browser doesn't support javascript.
loading
A New Approach to Objectively Evaluate Inherited Metabolic Diseases for Inclusion on Newborn Screening Programmes.
Burlina, Alberto; Jones, Simon A; Chakrapani, Anupam; Church, Heather J; Heales, Simon; Wu, Teresa H Y; Morton, Georgina; Roberts, Patricia; Sluys, Erica F; Cheillan, David.
Afiliação
  • Burlina A; Division of Inherited Metabolic Diseases, Reference Centre Expanded Newborn Screening, University Hospital Padova, 35128 Padova, Italy.
  • Jones SA; Willink Biochemical Genetics Unit, Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, St Mary's Hospital, Oxford Road, Manchester M13 9WL, UK.
  • Chakrapani A; Department of Metabolic Medicine, Great Ormond Street Hospital NHS Foundation Trust, London WC1N 3JH, UK.
  • Church HJ; Willink Biochemical Genetics Unit, Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, St Mary's Hospital, Oxford Road, Manchester M13 9WL, UK.
  • Heales S; Neurometabolic Unit, University College London Hospitals NHS Foundation Trust and Enzymes Laboratory, Great Ormond Street Hospital NHS Foundation Trust, London WC1N 3JH, UK.
  • Wu THY; Willink Biochemical Genetics Unit, Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, St Mary's Hospital, Oxford Road, Manchester M13 9WL, UK.
  • Morton G; ArchAngel MLD Trust, Registered Charity No. 1157825, 59 Warwick Square, London SW1V 2AL, UK.
  • Roberts P; ArchAngel MLD Trust, Registered Charity No. 1157825, 59 Warwick Square, London SW1V 2AL, UK.
  • Sluys EF; Helvet Health, Ruelle de la Muraz 4, 1260 Nyon, Switzerland.
  • Cheillan D; Service Biochimie et Biologie Moléculaire, Groupement Hospitalier Est, Hospices Civils de Lyon, 69002 Lyon, France.
Int J Neonatal Screen ; 8(2)2022 Mar 25.
Article em En | MEDLINE | ID: mdl-35466196
ABSTRACT
Newborn screening (NBS) programmes are essential in the diagnosis of inherited metabolic diseases (IMDs) and for access to disease modifying treatment. Most European countries follow the World Health Organisation (WHO) criteria to determine which disorders are appropriate for screening at birth; however, these criteria are interpreted and implemented by individual countries differently, creating disparities. Advances in research and diagnostics, together with the promise of new treatments, offer new possibilities to accelerate the expansion of evidence-based screening programmes. A novel and robust algorithm was built to objectively assess and prioritise IMDs for inclusion in NBS programmes. The Wilson and Jungner classic screening principles were used as a foundation to develop individual and measurable criteria. The proposed algorithm is a point-based system structured upon three pillars condition, screening, and treatment. The algorithm was tested by applying the six IMDs currently approved in the United Kingdom NBS programme. The algorithm generates a weight-based score that could be used as the first step in the complex process of evaluating disorders for inclusion on NBS programmes. By prioritising disorders to be further evaluated, individual countries are able to assess the economic, societal and political aspects of a potential screening programme.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article